title: [Effect of doxorubicin on TRAIL resistance and TRAIL receptor expression in lymphoma cell line SNK-6 cells].
abstract: OBJECTIVE
  To investigate the effect of doxorubicin on TRAIL resistance and TRAIL receptor expression in lymphoma cell line SNK-6 cells.
  
  
  METHODS
  SNK-6 cells treated with doxorubicin at different concentrations alone or in combination with tumor necrosis factor related apoptosis inducing ligand (TRAIL). Cell proliferation was evaluated by MTT assay. Apoptosis and the expression of TRAIL receptors were determined by flow cytometry.
  
  
  RESULTS
  MTT assay showed that treatment with 100 and 1000 ng/ml doxorubicin for 24 h, the survival rates of SNK-6 cells were (80.9 ± 7.2)% and (53.7 ± 2.8)%, significantly higher than that by treatment combined with 500 ng/ml TRAIL (64.9 ± 1.1)% and (34.0 ± 3.9)%, respectively (P < 0.05). Flow cytometry showed that after treatment with 100 and 1000 ng/ml doxorubicin for 48 h, the survival rates of SNK-6 cells were (69.9 ± 6.1)% and (31.1 ± 1.9)%, while treated in combination with 500 ng/ml TRAIL, the cell survival rates were (37.5 ± 6.4)% and (15.0 ± 1.8)%, respectively. The early apoptosis rate was (14.8 ± 0.6)% and (30.8 ± 1.5)%, significantly lower than that [(28.7 ± 0.6)% and (46.6 ± 2.8)%] after treatment in combination with TRAIL (P < 0.05). The expressions of TRAIL receptors and decoy receptors were increased when SNK-6 cells were treated with 100 ng/ml doxorubicin for 24 hours.
  
  
  CONCLUSIONS
  Doxorubicin can overcome to a certain extent the TRAIL resistance of SNK-6 cells and induce upregulation of TRAIL death receptors and decoy receptors on the surface of SNK-6 cells. However, a higher dose is needed.
authors: Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.
authors: Ying-chun
authors: YC
authors: Zhang
authors: Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.
authors: Qun-pei
authors: QP
authors: Yang
authors: Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.
authors: Yuan
authors: Y
authors: Tang
authors: Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.
authors: Wei-ya
authors: WY
authors: Wang
authors: Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.
authors: Jian-bo
authors: JB
authors: Yu
authors: Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China. Email: liuweiping2001@vip.sina.com.
authors: Wei-ping
authors: WP
authors: Liu
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000378:metabolism / Q000473:pathology*; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000494:pharmacology*; D053319:Tumor Necrosis Factor Decoy Receptors / Q000378:metabolism
chemical_list: D000903:Antibiotics, Antineoplastic; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D053221:TNF-Related Apoptosis-Inducing Ligand; D053319:Tumor Necrosis Factor Decoy Receptors; D004317:Doxorubicin